Thermo Fisher Scientific Inc. (NYSE:TMO) Shareholders to Receive $0.47 Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE:TMO) declared a quarterly dividend on Thursday, November 5th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.47 per share by the medical research company on Friday, January 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th.

Thermo Fisher Scientific has increased its dividend by an average of 0.1% per year over the last three years and has increased its dividend every year for the last 8 years. Thermo Fisher Scientific has a payout ratio of 7.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Thermo Fisher Scientific to earn $27.83 per share next year, which means the company should continue to be able to cover its $1.88 annual dividend with an expected future payout ratio of 6.8%.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $685.40 on Friday. Thermo Fisher Scientific has a one year low of $435.27 and a one year high of $712.17. The firm has a market cap of $253.95 billion, a price-to-earnings ratio of 36.01, a PEG ratio of 2.88 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a 50-day simple moving average of $659.74 and a two-hundred day simple moving average of $554.40.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion for the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the previous year, the firm earned $5.79 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific will post 25.26 EPS for the current fiscal year.

Insider Activity

In other news, EVP Michael Shafer sold 25,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 50,046 shares of company stock valued at $30,779,192 in the last quarter. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Keeler Thomas Management LLC increased its position in shares of Thermo Fisher Scientific by 0.9% during the 3rd quarter. Keeler Thomas Management LLC now owns 1,928 shares of the medical research company’s stock valued at $1,301,000 after purchasing an additional 17 shares during the period. Tsfg LLC lifted its holdings in shares of Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after buying an additional 19 shares during the period. Welch Group LLC boosted its stake in Thermo Fisher Scientific by 1.8% during the third quarter. Welch Group LLC now owns 1,089 shares of the medical research company’s stock valued at $735,000 after buying an additional 19 shares in the last quarter. Renasant Bank boosted its stake in Thermo Fisher Scientific by 1.0% during the second quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after buying an additional 20 shares in the last quarter. Finally, Strengthening Families & Communities LLC grew its holdings in Thermo Fisher Scientific by 0.4% during the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock worth $3,187,000 after acquiring an additional 21 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.

The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.